drugset / Trial / NCT06566261
ABA-101 in Participants With Progressive Multiple Sclerosis
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Timeline
- Start
- 2024-09-11
- Primary completion
- 2026-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABA-101 | Cell therapy | — | — |